Can-Fite nearing start of Piclidenoson study in COVID-19
Seeking Alpha · 07/27 11:49
Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study
Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study
Business Wire · 07/27 11:00
Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today it has completed the
Benzinga · 07/20 11:10
Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
Business Wire · 07/20 11:00
Can-Fite Announces $3.4 Million Registered Direct Offering
Business Wire · 07/06 13:00
Can-Fite plunges 10% on $3.4M direct offering
Seeking Alpha - Article · 07/06 12:38
Can-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period
Business Wire · 06/30 12:00
Can-Fite announces final data from mid-stage study of Namodenoson in NASH
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.